Semaglutide FDA approval date

The FDA approved Semaglutide (Wegovy) on 5 Dec 2017.

FDA approval date
5 Dec 2017

Drug identity checked against registry records

Also recorded as Wegovy

Included trials

TrialSponsorPhaseStatusPrimary completion
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight MgmtNCT06282458VERUPhase 2Completed2025-04-11Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2017-12-05DaySemaglutideFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA209637", "applicant_as_listed_by_fda": "NOVO", "brand_names": ["OZEMPIC"], "active_ingredients": ["SEMAGLUTIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20171205", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026